未登录

B

Benjamin Wu

Amgen

H指数:22

被引数:1,757

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Harnessing Quantitative Medicine to Advance Oncology Drug Development

利用定量医学推动肿瘤药物研发

CTS-Clinical and Translational Science

IF2.8

2026-09-290

OAAI

Correction: Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates

更正：Atezolizumab的免疫原性：检测方法和采样频率对报告的抗药抗体发生率的影响

IF0

2025-06-200

OA

IQ Survey Results on Current Industry Practices: Part 2-Quantitative Evaluations of Immunogenicity Assessment

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2025-02-070

OAAI

Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-02-050

OA

IQ Survey Results on Current Industry Practices-Part 1: Immunogenicity Risk Assessment

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2025-01-280

OAAI

Integrating real-world data and machine learning: A framework to assess covariate importance in real-world use of alternative intravenous dosing regimens for atezolizumab

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-11-180

OAAI

Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates

IF3.7

2024-07-152

PRE

Applications of Advanced Natural Language Processing for Clinical Pharmacology

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-01-245

OAAI

Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-06-026

PRE

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

CLINICAL CANCER RESEARCH

IF10.2

2023-01-0311

OA

Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study

IF3.7

2022-04-286

PRE

Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy

IF8.3

2022-02-0111

OAAI

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-09-2821

OA

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-08-2538

OAAI

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2021-08-0424

OAAI

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region

IF9.1

2021-06-1014

OAAI

Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities

MOLECULAR THERAPY

IF12

2021-02-01165

OAAI

Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-12-0729

OAAI

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2019-07-0537

PREAI

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2017-06-094

PREAI